Background: Lung adenocarcinoma represents a major contributor to cancer mortality and is increasingly found in non-smoking patients. EGFR mutations serve as key determinants of pathogenesis and guide first- through third-generation EGFR-TKI therapy. However, local data on mutation prevalence and clinical characteristics remain limited. This study aims to describe patient characteristics, mutation patterns, and the use of TKIs at General Hospital of Muhammadiyah Malang University. Methods: A retrospective cohort study was conducted on all lung adenocarcinoma patients from 2015–2020. Clinical profiles, genetic testing results, and survival were analyzed descriptively from medical records. Results: Among 152 patients, the mean age was 58.9 years, with a male predominance. Most specimens were cytology samples. EGFR mutations were identified in 36.9% of cases, primarily Del19 and L858R. In a subgroup of 21 patients who underwent NGS, the mean age was 61 years, and EGFR remained the most frequent mutation (38.1%). In total, 17 mutations were detected, dominated by EGFR, followed by TP53, KRAS, BRAF, ALK fusion, and STK11. Discussion: The prevalence of EGFR mutations aligns with patterns reported in Asian populations and supports the use of EGFR-TKIs, including osimertinib as a first-line option. Mutation diversity identified through NGS underscores the need for comprehensive molecular profiling. Conclusion: EGFR mutations are highly prevalent in this population, dominated by Del19 and L858R. NGS reveals additional actionable alterations, highlighting the importance of broad molecular testing and the need for larger studies in Indonesia. Keywords: Lung Adenocarcinoma, EGFR Mutation, Tyrosine Kinase Inhibitor (TKI), Next-Generation Sequencing (NGS), Genomic Profile
Copyrights © 2026